RxDoctor Payments Data

Audrey Hubler

Family · Joplin, MONPI 1831754720

Payments from drug & device makers

$695in general payments, 2019–2025

Across 30 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$161
  • AstraZeneca$77
  • Boehringer Ingelheim$51
  • Lilly USA, LLC$46
  • Novartis$45
  • Sumitomo Pharma America, Inc.$41
  • plus $273 from 11 others

What the payments were for

  • Food & beverage$695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695 in reported general payments places this provider in the 60th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$23,818
Medicare patients
161
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide26$27,397
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$23,548
EliquisApixaban23$16,121
LinzessLinaclotide11$11,178
XareltoRivaroxaban18$10,088
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,893
Gabapentin122$2,487
Albuterol Sulfate HfaAlbuterol Sulfate60$1,595
Atorvastatin Calcium135$1,114
Amlodipine Besylate114$764
Tizanidine Hcl42$716
Omeprazole60$669
Bupropion XlBupropion Hcl17$600
Pregabalin23$595
Celecoxib30$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$46$27,39726 claims
GSKTrelegy Ellipta$14$23,54832 claims
AbbVieLinzess$40$11,17811 claims
Johnson & JohnsonXarelto$27$10,08818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,812 family providers in Missouri.

Other family in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →